作者：姜瑞嘉1 ，程功1 ，王依阳1 ，蒋红英1 ，赵慧1 ，梁宸源1 ，许百灵2 ，方纬3

单位：

1.710068陕西省西安市，陕西省人民医院心血管内科　2.65211美国哥伦比亚，密苏里大学哥伦比亚分校核 科学暨工程研究所　3.100037北京市，中国医学科学院阜外医院核医学科

Units：

1.Department of Cardiovascular, Shaanxi Provincial People's Hospital, Xi'an 710068, China 2.Institute of Nuclear Science and Engineering, the University of Missouri in Columbia, Columbia 65211, America 3.Nuclear Medicine Department, Fuwai Hospital, CAMS & PUMC, Beijing 100037, China

关键词：

冠心病；冠状动脉微血管疾病；经皮冠状动脉介入治疗；葛兰心宁软胶囊；多配体蛋白聚糖1；多 配体蛋白聚糖4；硫酸乙酰肝素

Keywords：

Coronary disease; Coronary microvascular disease; Percutaneous coronary intervention; Gelan Xinning soft capsules; Syndecan-1; Syndecan-4; Heparitin sulfate

CLC：

R 541.4

DOI：

10.12114/j.issn.1008-5971.2024.00.116

Funds：

陕西省中医药管理局委托办事经费任务（2021-ZZ-ZY003）；陕西省人民医院科技发展孵化基金项目（2021YJY- 17）；陕西省人民医院科技人才支持计划项目（2022LJ-04）

摘要：

　目的　分析葛兰心宁软胶囊对PCI后合并冠状动脉微血管疾病（CMVD）的冠心病患者血浆多配体蛋 白聚糖（SDC）1、SDC4、硫酸乙酰肝素（HS）的影响。方法　选取2021年7月—2022年9月陕西省人民医院心血管内 科收治的PCI后合并CMVD的冠心病患者78例为研究对象。采用随机数字表法将患者分为葛兰心宁软胶囊组（38例）和 对照组（40例）。对照组接受常规治疗，葛兰心宁软胶囊组在常规治疗的基础上加服葛兰心宁软胶囊，两组治疗时间 均为2个月。比较两组一般资料、临床疗效，治疗前后血浆SDC1、SDC4、HS及其差值，治疗期间不良反应发生率。结 果　葛兰心宁软胶囊组临床疗效优于对照组（P＜0.05）。治疗后，葛兰心宁软胶囊组血浆SDC1、SDC4、HS低于对照 组（P＜0.05）；葛兰心宁软胶囊组治疗前后血浆SDC1、SDC4、HS差值大于对照组（P＜0.05）。两组治疗期间胃肠 道不适、过敏、出血、肾功能异常发生率比较，差异无统计学意义（P＞0.05）。结论　葛兰心宁软胶囊可有效降低 PCI后合并CMVD的冠心病患者血浆SDC1、SDC4、HS。

Abstract：

Objective To analyze the effect of Gelan Xinning soft capsule on plasma syndecan (SDC) -1, SDC-4 and heparitin sulfate (HS) in coronary heart disease patients with coronary microvascular disease (CMVD) after PCI. Methods Seventy-eight coronary heart disease patients with CMVD after PCI admitted to the Department of Cardiovascular, Shaanxi Provincial People's Hospital from July 2021 to September 2022 were selected as the study objects. The patients were divided into Gelan Xinning soft capsule group (38 cases) and control group (40 cases) by random number table method. The control group received conventional treatment, and the Gelan Xinning soft capsule group took Gelan Xinning soft capsule on the basis of conventional treatment. The treatment time of both groups was 2 months. The general data, clinical efficacy, plasma SDC1, SDC4, HS and their differences before and after treatment, and the incidence of adverse reactions during treatment were compared between the two groups. Results The clinical effect of Gelan Xinning soft capsule group was better than that of control group (P < 0.05) . After treatment, plasma SDC1, SDC4 and HS in Gelan Xinning soft capsule group were lower than those in control group (P < 0.05) . The difference of plasma SDC1, SDC4 and HS before and after treatment in Gelan Xinning soft capsule group was greater than that in control group (P < 0.05) . There was no significant difference in the incidence of gastrointestinal discomfort, allergy, bleeding and abnormal kidney function between the two groups during treatment (P > 0.05) . Conclusion Gelan Xinning soft capsule can effectively reduce the plasma SDC1, SDC4 and HS of coronary heart disease patients with CMVD after PCI.

ReferenceList：